StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries GAAP Share-Based Compensation Expense by Quarter

GAAP Share-Based Compensation Expense ($M)

Teva Pharmaceutical Industries GAAP Share-Based Compensation Expense: $38M in Q3 2026, up 11.8% from a year earlier.

Latest, Q3 2026
38
Period ended Sep 30, 2026
Change on a year earlier
+11.8%
34 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

Source: SEC Form 10-Q (0000818686-26-000006) ↗

Reported in Database (financial_values) & SEC Form 10-Q / 10-K.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGAAP Share-Based Compensation Expense ($M)Year on yearSource
Q3 2026Sep 30, 202638+11.8%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2026Jun 30, 202640+5.3%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2026Mar 31, 202643+26.5%SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2025Dec 31, 202551+50.0%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2025Sep 30, 202534+17.2%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2025Jun 30, 202538+18.8%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2025Mar 31, 202534+21.4%SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2024Dec 31, 202434+21.4%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2024Sep 30, 202429-6.5%SEC Form 10-Q (0001193125-25-266895) ↗
Q2 2024Jun 30, 202432+6.7%SEC Form 10-Q (0001193125-25-169296) ↗
Q1 2024Mar 31, 202428-12.5%SEC Form 10-Q (0001193125-25-114889) ↗
Q4 2023Dec 31, 202328-22.2%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2023Sep 30, 202331+19.2%SEC Form 10-Q (0001193125-24-252039) ↗
Q2 2023Jun 30, 202330-23.1%SEC Form 10-Q (0001193125-24-189924) ↗
Q1 2023Mar 31, 202332+33.3%SEC Form 10-Q (0001193125-24-134200) ↗
Q4 2022Dec 31, 202236+9.1%SEC Form 10-K (0001193125-25-020826) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries GAAP Share-Based Compensation Expense ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/db-cf-sbc

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?